ERBB2 and non-small cell lung carcinoma: A multicenter retrospective study showed an ORR, DCR, and median PFS of 38.5%, 84.6%, and 7.4 months, respectively for 26 patients with HER2-mutant NSCLC, including 16 patients treated with immunochemotherapy combination regimens [114].